New Study Pinpoints Emergence Of First Animals
The Ediacaran, a geological period spanning from 635 to 538 million years ago, saw the emergence of the first complex multicellular animals after Earth was ruled for almost 3 billion years by microorganisms.
First described from the Ediacara Hills in Australia, Ediacara-type fossils have been found in Newfoundland, England's Charnwood Forest, Namibia, Russia and China.
The Ediacara fossils includes many weird organisms of unknown affinity, like Dickinsonia, an egg-shaped, segmented hybrid between a worm and a jellyfish, Charnia, a segmented and branched organism resembling superficially modern sea pens, or Tribrachidium, showing a threefold rotational symmetry not found in any modern creature.
The beginning of the Ediacaran is marked by the Marinoan glaciation, a worldwide glaciation lasting from 654 to 632 million years ago. Its possible role in the emergence of the Ediacaran fauna has long been debated, with some researchers suggesting that the melting ice released nutrients into the sea, providing a fertile ground for complex life to evolve.
In a new study, Chinese researchers used cyclostratigraphy to exactly date the aftermath of the Marinoan glaciation and the emergence of the Ediacara fauna, suggesting that oxygen pulses played a mayor role.
Cyclostratigraphy analyzes astronomically-forced cycles preserved in sedimentary rocks. When integrated with radioisotope geochronology, a technology that uses the radioactive decay of elements to date rocks and minerals, it can produce a continuous, high-resolution geological time scale.
Approximately 580 million years ago, South China was part of the northern coastline of the supercontinent Rodinia and positioned near the equator. The erosion of the still barren land produced a succession of black mudstone and white limestone layers. By studying this succession, the researchers discovered cycles lasting from 2.4 million years to 103,000 years, likely a result of orbital changes and shifting climate patterns.
According to the new analysis, the Marinoan ice age was followed by a rapid sea-level rise, leading to the deposition of a thick layer of cap carbonate in just one to 10 million years. This marks a dramatic shift from a frozen world to a hot, high-carbon dioxide environment.
The emergence of the earliest Ediacara-type fossils was dated to 619 to 587 million years, with species becoming progressively more complex over time. The rapid deglaciation influenced oceanic currents, leading to periodic pulses of oxygen reaching the deep sea. The emergence of new species, so the study's conclusions, coincides with these oxygenation events.
The flattened body of many Ediacaran fossils suggests they adsorbed oxygen and nutrients directly from the water through their body surface. But this adaption made them vulnerable to low oxygen levels. A combination of volcanic eruptions, tectonic plate motion, maybe even an asteroid impact, at the end of the Ediacaran caused a drop in global oxygen levels, leading to the first mass extinction around 539 to 500 million years ago
This extinction may have helped pave the way for the evolution of animals as we know them today.
The study, "Astronomically calibrating early Ediacaran evolution," was published in the journal nature communications.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 days ago
- Forbes
A New Chapter For Diabetes—and Regenerative Medicine
For decades, the ambitious goal of regenerative medicine has been to replace damaged or lost tissues with healthy, functioning ones. Nowhere is this objective more compelling—or challenging—than in type 1 diabetes. Countless research efforts over the years have sought to restore these cells. Breakthroughs in cell engineering and transplantation are beginning to overcome long-standing roadblocks, and these recent advances are a significant achievement for regenerative medicine as a whole. For millions living with the constant demands and worries of type 1 diabetes, this is more than promising data. It's a moment that hints at a world where glucose monitors and needles might finally become relics of the past. With this, a life free from the daily burdens of diabetes suddenly feels not just possible, but Is Type 1 Diabetes? Type 1 diabetes is a chronic autoimmune disorder defined by the immune system's destruction of insulin-producing beta cells in the pancreas. Insulin is the hormone responsible for moving glucose from the bloodstream into the body's cells for energy. Without it, blood sugar rises to dangerous levels. Over time, it can damage virtually every organ. Most people diagnosed are children or young adults, and living with type 1 diabetes requires ongoing vigilance: regular blood glucose testing, carefully calibrated insulin administration, and persistent risk of life-threatening hypoglycemia. To survive, people with type 1 diabetes must monitor their blood sugar levels constantly. They frequently perform fingerstick tests throughout the day to check their blood glucose levels. Also, they must adjust their diet, exercise routine, and daily schedule to accommodate frequent insulin injections or an insulin pump. Despite advances in technology, keeping blood glucose within a safe range remains challenging, and the risk of life-threatening 'hypoglycemic' episodes—when blood sugar drops too low—is Stem Cell Therapy: Replacing What's Lost This is where the new therapies come into play. They go straight to the heart of the problem: the loss of the body's own insulin-producing cells. Instead of requiring patients to rely on lifelong injections, the focus is now on developing stem cells grown in controlled laboratory environments. These stem cells are engineered to become fully functional islet cells. These are the very clusters that regulate blood sugar in a healthy pancreas. The "off-the-shelf" nature of these cells is crucial. Earlier islet transplant procedures relied on donated organs, which are rare, variable in quality, and subject to lengthy waitlists. The engineered cells, on the other hand, are produced in large quantities. Also, they can be made available as needed. When infused, typically into the liver, these new cells integrate and begin responding to blood sugar levels in real time, releasing insulin as needed. In essence, the therapy is designed to restore the natural balance lost due to the disease. The promise of this approach is already becoming a the Latest Study The most recent results in the development of stem cell–derived therapies for type 1 diabetes stem from a clinical trial conducted by Vertex Pharmaceuticals. This study enrolled patients with established, severe type 1 diabetes. This is a group for whom current treatments often fail to prevent sudden and dangerous drops in blood sugar. Each patient in the trial received a single infusion of lab-grown islet cells, now referred to as zimislecel. To translate the science: the stem cells are first turned into insulin-producing islet cells in the lab. These are then infused into the patient's liver, not the pancreas. If successful, they begin sensing blood sugar levels and releasing insulin as needed, just like a healthy pancreas would. Think of this as swapping out a faulty part with a working one, rather than relying on external fixes. The results over twelve months were consistent and dramatic. All participants in the study were found to be producing their own insulin again. This was confirmed by checking bloodwork to verify that the islet cells were now active. Therefore, the transplanted cells integrated well, and the patients' bodies were able to produce insulin naturally for the first time in years. Even more remarkably, ten of these individuals were able to discontinue daily insulin injections entirely. Every participant met or surpassed the American Diabetes Association's stringent targets for glycemic control. Notably, none suffered severe hypoglycemic This Matters: The Science and Its Impact These results represent a shift in the care landscape for type 1 diabetes. Previous attempts at islet cell replacement used donor cells, which were in very limited supply. By creating islets from universal stem cells, this therapy can be scaled up. It brings the possibility of universal therapies with consistent quality and availability. This offers real hope to millions worldwide. It also signals a foundational advance in regenerative medicine itself. Demonstrating that we can produce, transplant, and integrate functional cell populations to cure a chronic, complex condition illustrates the practical power of stem cell technology. The methodology used here is already being adapted for other therapeutic targets: engineered heart muscle for cardiac repair, retinal cells for vision restoration, and dopaminergic neurons for Parkinson's disease. It establishes a blueprint for tackling similar disorders and builds a bridge from bench research to real-world clinical impact. These advances, however, are not without their complexities. Because the transplanted islet cells are not the patient's own, recipients currently require immunosuppressive medications to prevent rejection—a challenge shared by all current forms of tissue and organ transplantation. Although initial safety profiles are encouraging and side effects manageable, ongoing studies are exploring methods to reduce or eliminate immune suppression, such as gene editing and immune cloaking Road Ahead: What's Next? The achievements described here are far more than incremental progress in diabetes care. They represent proof-of-concept for the broad ambitions of regenerative medicine: restoring lost tissue function, curing chronic diseases, and making transformative treatments widely accessible. As these strategies mature and diversify, their impact will almost certainly extend well beyond any single disease. They offer a pathway to fundamentally change how we approach a broad spectrum of degenerative and autoimmune conditions. The future of regenerative medicine, once hypothetical and distant, now approaches with real hope for curing—not simply managing—a host of devastating chronic conditions.
Yahoo
7 days ago
- Yahoo
Eating too many French fries could increase risk of Type 2 diabetes: Study
Apparently, there is such a thing as too many French fries. And it's also not just about the amount of fries you could be eating in one sitting but also how many times a week you consume the tasty taters a week that could increase an individual's risk of developing Type 2 diabetes. According to a study published in the British Medical Journal, eating three or more servings of fries each week can increase the chance of developing the chronic condition by 20%, while eating fries five times a week can increase the chance by 27%. 'Our findings underscore that the association between potato intake and type 2 diabetes risk depends on the specific foods used as replacement,' the researchers said. 'The findings also align with current dietary recommendations that promote the inclusion of whole grains as part of a healthy diet for the prevention of type 2 diabetes.' The researchers did note that eating similar amounts of potatoes cooked other ways — boiled, baked or mashed, for example — does not substantially increase the risk, only reducing it by 5%. 'The high starch content of potatoes, leading to a high glycemic index and load, combined with possible loss of nutrients and possible health risks resulting from various cooking methods, could contribute to adverse health outcomes,' the study explains. More than 22,000 cases of Type 2 diabetes were documented during the 37-year time period. RECOMMENDED VIDEO 'Potatoes can be part of a healthy diet, but it's how we prepare them that makes the difference,' Dr. Kawther Hashem, a lecturer in public health nutrition at Queen Mary University of London and not involved with the study, told the Guardian. 'Boiled, baked or mashed potatoes are naturally low in fat and a source of fibre, vitamin C and potassium,' Hashem continued. 'But when we deep fry them into French fries, especially in large portions and with added salt, they become less healthy with their high-fat, salt and calorie content that's much more likely to contribute to weight gain and increase the risk of type 2 diabetes.' For the study, an international team of researchers examined the diets of more than 205,000 adults in the United States who had their eating habits documented every four years between 1984 and 2021. Sink your teeth into this: Red meat again linked to Type 2 diabetes risk Dark chocolate may lower risk of developing Type 2 diabetes SYRON: Misleading diabetes ads on social media pose a serious health risk 'Not all potatoes are created equal,' lead author Seyed Mohammad Mousavid, a research fellow at the Harvard T.H. Chan School of Public Health, told NBC News. 'Even a small amount of french fries, less than one serving in the week, is associated with a higher risk of Type 2 diabetes.' Replacing potatoes with whole grains, on the other hand, lowers the risk of diabetes by 8%, and if grains are eaten instead of fries specifically, that cuts the risk by 19%. White rice, however, had a stronger association with diabetes.
Medscape
7 days ago
- Medscape
Transplanted Islet Cells Survive Without Immune Suppression
For the first time, researchers have transplanted gene-edited donor islet cells that secrete insulin in a person with type 1 diabetes (T1D) without the use of immunosuppression. Twelve-week results from the phase 1, single-participant study were published online on August 4, 2025, as a Brief Report in The New England Journal of Medicine . Six-month data were presented on June 23, 2025, at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago and announced at the time in a press release from Sana Biotechnology. The study subject, a 42-year-old man with a 37-year history of T1D, has shown no immune response to the gene-edited cells and has maintained ongoing significant circulating C-peptide levels, a measure of insulin secretion, in contrast to zero at baseline. MRI at 12 weeks confirmed persistence of the grafted hypoimmune islets. At 6 months, increased C-peptide levels in response to a mixed-meal tolerance test were seen. He still requires insulin treatment, but that was expected because the protocol for this early safety study involved delivery of only 7% of the number of cells that would be curative, lead author Per-Ola Carlsson, MD, PhD, senior physician and professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital, Uppsala, Sweden, told Medscape Medical News . 'Excited,' but 'Many Hurdles to Overcome' Currently, transplantation for treatment of T1D — whether of whole pancreas, cadaveric donor islets, or experimental stem cell-derived islets — is reserved for individuals with frequent severe hypoglycemia or those who are already undergoing another transplant, such as a kidney. In most people with managed T1D, the adverse health risks for immune suppression are viewed as outweighing the benefits of a transplant. In T1D, transplantation provokes two immune system attacks: one against any foreign body, which is common to all organ transplants (allogeneic), and a second to the beta cell-specific autoantibodies that caused the condition in the first place. Thus far, it appears that this novel gene-editing approach overcomes both allogeneic and autoimmune rejection. If upcoming trials using stem cell-derived islets that can be produced in unlimited quantities validate these results, this approach could essentially represent a cure for many people T1D, Carlsson said. 'I have never been so excited in my life. I've been working with the science since the 1990s, and this is the one project that has been so positive and so convincing. I'm really happy to work with it, and since I'm a clinician, it's magic to be able to do something that could turn into a reality for these patients,' he told Medscape Medical News . However, he cautioned, 'This is one subject…we believe it is applicable to all subjects with type 1 diabetes. But of course, there may be subgroups that it does not work for.' Moreover, he noted, 'It will take time before it reaches clinical reality.' Experts in the field contacted by Medscape Medical News expressed cautious optimism. Mark A. Atkinson, PhD, the ADA Eminent Scholar for Diabetes Research and professor in the Department of Pathology at the University of Florida, Gainesville, Florida, said, 'I am very enthusiastic about this study. I think this is a baby step, with the potential for moving forward a full leap. Time will tell. At a minimum, this shows that genetic modification of a stem cell source may prove valuable as a future therapeutic for type 1 diabetes.' However, Atkinson noted that because the treatment is likely to be expensive, 'the cost versus benefit ratio of using such a therapy across the spectrum of type 1 diabetes needs further exploration.' Islet cell transplantation pioneer A.M. James Shapiro, MD, Canada Research Chair in Transplantation Surgery and Regenerative Medicine at the University of Alberta, Edmonton, Alberta, told Medscape Medical News 'This is indeed an exciting development in that human insulin-producing islet cells continued to secrete, albeit small amounts of insulin in the absence of immune suppression. Ongoing research will determine whether this approach can be effectively scaled up and engraftment improved.' David M. Harlan, MD, director of the Breakthrough T1D Barbara D. Cammett Center of Excellence in New England and co-director of the University of Massachusetts (UMass) Diabetes Center of Excellence, Worcester, Massachusetts, said, 'I believe that the genetic modifications of stem cell-derived islets and/or a druggable target within a stem cell-derived islet is likely to represent a practical cure for type 1 diabetes in the next decade or so. I'm excited by this step, but I still see many hurdles to overcome.' Hypoimmune Islets: Breakthrough or Baby Step? Some of the 'hurdles' cited by Harlan, who is also the William and Doris Krupp Professor of Medicine at UMass, relate to the gene-editing procedure itself and to some of the study methodology. The islets, from a deceased donor with the same blood type as the recipient, were first dissociated into single cells, and the genes encoding human leukocyte antigen (HLA) class I and class II were inactivated using clustered regularly interspaced short palindromic repeat. The cells were reclustered, again dissociated, and transduced with a lentiviral vector containing CD47 complementary DNA. Knocking out HLA class I and II is necessary to protect against adaptive T-cell rejection, while overexpression of CD47 inhibits innate killing via macrophages and natural killer cells, Carlsson explained. According to Harlan, even without HLA class I and II, there would still be other cell surface molecules that would be expected to provoke an antibody response. 'I just don't understand why they don't see any donor-specific antibodies against the gene-modified islets. That doesn't make sense to me. Maybe such antibodies would be benign, but I would still expect them to be picked up.' Carlsson countered, 'Detection of foreign cells is through HLA. Other antigens…are, even if not encoded from the HLA class I or class II genes, presented to the immune system by the HLA molecules.' Atkinson noted that the autoimmune response could take much longer to occur than the allogeneic, and therefore longer follow-up is needed. Carlsson said that the planned follow-up is 15 years, but prior data suggest that the autoimmunity would occur within 1-2 months, and 'we didn't see any attack at all.' Harlan also noted that the patient's high baseline A1c, 10.9%, was unusual and might have adversely affected the findings. Carlsson said that this was per request of the regulatory bodies because such an individual would 'gain most from the development of a curing therapy considering their high risk of complications.' He added that this requirement 'complicated the study since high glucose stresses the beta cells…we were, however, able to improve his metabolic control post-transplantation.' The gene-edited cells were delivered with 17 separate injections — to allow for sufficient oxygen exposure — into the patient's forearm while he was under general anesthesia. Both Harlan and Atkinson questioned the feasibility of that approach going forward. Carlsson said that the forearm was chosen because it was simpler to monitor for safety, but that in future studies abdominal muscles might be used. Sana Biotechnology will not study this product, UP421, further. Instead, they are moving forward with SC451, a stem cell-derived pancreatic gene-edited islet cell product. The next study is still being planned but will involve multiple patients at more than one clinical site, Carlsson told Medscape Medical News . Atkinson commented, 'Over 50 years ago, individuals with type 1 diabetes were told that a cure was on the way, and it was going to occur through islet cell transplantation and understanding of the autoimmune nature of type 1 diabetes. There were animal models of the disease, and there were new classes of drugs that came out, namely cyclosporine. So, people had hopes that a cure for type 1 diabetes was 3-5 years away. Now, six decades later, we're still struggling with that, but there's promise on the horizon.' Carlsson and Shapiro reported having no disclosures. Atkinson is a consultant for Vertex, Sanofi, Diamyd, Novo Nordisk, and Sernova. Harlan is co-founder and chief scientific officer for Stability Health, LLC; a consultant for CG Scientific, Inc.; and chair of the scientific advisory board for TIXiMED.
